TABLE 4

Univariate analysis of factors associated with 30-day mortality

VariableaValue for the survival periodbP valued
Death within 30 days (n = 46)Survival to 30 days (n = 95)
Baseline patient characteristics
    Age (yr)c67 (55–73)59 (49–74)0.1
    Male sex25 (54)61 (64)0.3
    CCIS of ≥431 (67)46 (48)0.03*
    Immunosuppressed14 (30)51 (54)0.009*
    Neutropenic2 (4)10 (11)0.3
Severity of illness at time of BSI
    In or transferred to the ICU within 48 h36 (78)51 (54)0.005*
    Serum creatinine (mg/dl)c1.25 (0.9–2.5)1.5 (0.9–2.2)0.5
    Serum WBC (109/liter)c13.1 (8.1–17.9)10.6 (6.9–17.7)0.07
    Serum albumin (g/dl)c2.4 (2.0–2.8)2.5 (2.1–3.0)0.08
    RRT23 (50)25 (26)0.005*
    PBS of ≥434 (74)27 (28)<0.0001*
    Septic shock24 (52)19 (20)0.0001*
BSI treatment-related factors
    Days from BSI to active therapy1 (0–3)2 (1–3)0.4
    Source control within 7 days29 (67)49 (67)1.0
Presumed source of BSI
    Catheter-associated3 (7)7 (7)0.7
    Respiratory tract8 (17)11 (12)
    Intra-abdominal11 (24)21 (22)
    Mucosal translocation4 (9)8 (8)
    Soft tissue or wound2 (4)5 (5)
    Urinary tract6 (13)25 (26)
    Multiple10 (22)13 (14)
    Unknown2 (4)5 (5)
Initial isolate susceptibility (MIC)
    Cefepime (≤8 μg/ml)12 (39)18 (36)0.8
    Meropenem (≤8 μg/ml)3 (8)8 (11)1.0
    Polymyxin B (≤2 μg/ml)35 (83)70 (84)0.9
    Tigecycline (≤2 μg/ml)38 (86)74 (86)0.9
  • a CCIS, Charlson comorbidity index score; BSI, bloodstream infection; ICU, intensive care unit; WBC, white blood cell count; RRT, renal replacement therapy; PBS, Pitt bacteremia score.

  • b Values represent the number (%) of patients unless otherwise indicated.

  • c Values are medians (interquartile range).

  • d Significant differences are indicated (*, P < 0.05).